Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources.

Elzembely MM, Park JR, Riad KF, Sayed HA, Pinto N, Carpenter PA, Baker KS, El-Haddad A.

J Glob Oncol. 2018 Sep;(4):1-12. doi: 10.1200/JGO.17.00118.

PMID:
30241255
2.

Late effects in high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell rescue.

Elzembely MM, Dahlberg AE, Pinto N, Leger KJ, Chow EJ, Park JR, Carpenter PA, Baker KS.

Pediatr Blood Cancer. 2018 Aug 27:e27421. doi: 10.1002/pbc.27421. [Epub ahead of print]

PMID:
30151986
3.

Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease.

El-Jawahri A, Pidala J, Khera N, Wood WA, Arora M, Carpenter PA, Palmer J, Flowers ME, Jagasia M, Chen YB, Lee SJ.

Biol Blood Marrow Transplant. 2018 Jul 20. pii: S1083-8791(18)30408-7. doi: 10.1016/j.bbmt.2018.07.020. [Epub ahead of print]

PMID:
30031937
4.

A phase II/III randomized, multicenter trial of Prednisone /Sirolimus vs Prednisone/Sirolimus/Calcineurin Inhibitor for treatment of chronic graft-versus-host disease: BMT CTN 0801.

Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M; Blood and Marrow Clinical Trials Network.

Haematologica. 2018 Jun 28. pii: haematol.2018.195123. doi: 10.3324/haematol.2018.195123. [Epub ahead of print]

5.

Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation.

Sullivan KM, Majhail NS, Bredeson C, Carpenter PA, Chatterjee S, Crofford LJ, Georges GE, Nash RA, Pasquini MC, Sarantopoulos S, Storek J, Savani B, St Clair EW.

Biol Blood Marrow Transplant. 2018 Jun 25. pii: S1083-8791(18)30362-8. doi: 10.1016/j.bbmt.2018.06.025. [Epub ahead of print]

PMID:
29953945
6.

Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients.

Jamani K, Onstad LE, Bar M, Carpenter PA, Krakow EF, Salit RB, Flowers MED, Lee SJ.

Biol Blood Marrow Transplant. 2018 Jun 21. pii: S1083-8791(18)30327-6. doi: 10.1016/j.bbmt.2018.06.015. [Epub ahead of print]

PMID:
29935213
7.

ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.

Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M, Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J, DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1119-1124. doi: 10.1016/j.bbmt.2018.03.023. Epub 2018 Mar 30.

PMID:
29608957
8.

Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease.

Lee SJ, Nguyen TD, Onstad L, Bar M, Krakow EF, Salit RB, Carpenter PA, Rodrigues M, Hall AM, Storer BE, Martin PJ, Flowers ME.

Biol Blood Marrow Transplant. 2018 Mar;24(3):555-562. doi: 10.1016/j.bbmt.2017.10.042. Epub 2017 Nov 10.

PMID:
29133250
9.

Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.

Chen GL, Carpenter PA, Broady R, Gregory TK, Johnston LJ, Storer BE, Beumer JH, Qiu J, Cerda K, Le R, Otani JM, Liu H, Ross MA, Arai S, Flowers MED, McCarthy PL, Miklos DB.

Biol Blood Marrow Transplant. 2018 Feb;24(2):373-380. doi: 10.1016/j.bbmt.2017.10.021. Epub 2017 Oct 16.

PMID:
29051021
10.

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1826-1838. doi: 10.1016/j.bbmt.2017.07.027. Epub 2017 Aug 7.

PMID:
28797780
11.

Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia.

Carpenter PA, Johnston L, Fernandez HF, Radich JP, Mauro MJ, Flowers MED, Martin PJ, Gooley TA.

Blood. 2017 Aug 31;130(9):1170-1172. doi: 10.1182/blood-2017-03-771121. Epub 2017 Jul 11. No abstract available.

12.

Vitamin A to reduce gut leak and GVHD?

Carpenter PA.

Blood. 2017 May 18;129(20):2715-2717. doi: 10.1182/blood-2017-03-773226. No abstract available.

13.

An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.

Martin PJ, Storer BE, Inamoto Y, Flowers MED, Carpenter PA, Pidala J, Palmer J, Arora M, Jagasia M, Arai S, Cutler CS, Lee SJ.

Blood. 2017 Jul 20;130(3):360-367. doi: 10.1182/blood-2017-03-775767. Epub 2017 May 11.

14.

Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease.

Inamoto Y, Martin PJ, Paczesny S, Tabellini L, Momin AA, Mumaw CL, Flowers MED, Lee SJ, Carpenter PA, Storer BE, Hanash S, Hansen JA.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1250-1256. doi: 10.1016/j.bbmt.2017.04.019. Epub 2017 Apr 25.

15.

Recipient and donor age impact the risk of developing chronic GvHD in children after allogeneic hematopoietic transplant.

Watkins BK, Horan J, Storer B, Martin PJ, Carpenter PA, Flowers ME.

Bone Marrow Transplant. 2017 Apr;52(4):625-626. doi: 10.1038/bmt.2016.328. Epub 2016 Dec 19. No abstract available.

PMID:
27991888
16.

Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.

Martin PJ, Fan W, Storer BE, Levine DM, Zhao LP, Warren EH, Flowers ME, Lee SJ, Carpenter PA, Boeckh M, Hingorani S, Yan L, Hu Q, Preus L, Liu S, Spellman S, Zhu X, Pasquini M, McCarthy P, Stram D, Sheng X, Pooler L, Haiman CA, Sucheston-Campbell L, Hahn T, Hansen JA.

Blood. 2016 Nov 17;128(20):2450-2456. Epub 2016 Oct 6.

17.

Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.

Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, Wingard JR, Paci A, Hassan M, Bredeson C, Pidala J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925. doi: 10.1016/j.bbmt.2016.07.013. Epub 2016 Jul 29. Review.

18.

Genetic risk factors for sclerotic graft-versus-host disease.

Inamoto Y, Martin PJ, Flowers ME, Lee SJ, Carpenter PA, Warren EH, Geraghty DE, Lee N, Boeckh MJ, Storer BE, Levine DM, Fan W, Zhao LP, Hansen JA.

Blood. 2016 Sep 15;128(11):1516-24. doi: 10.1182/blood-2016-05-715342. Epub 2016 Jun 16.

19.

Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity.

Aki SZ, Inamoto Y, Carpenter PA, Storer BE, Sandmaier BM, Lee SJ, Martin PJ, Flowers ME.

Bone Marrow Transplant. 2016 Oct;51(10):1350-1353. doi: 10.1038/bmt.2016.131. Epub 2016 May 23.

20.

How I vaccinate blood and marrow transplant recipients.

Carpenter PA, Englund JA.

Blood. 2016 Jun 9;127(23):2824-32. doi: 10.1182/blood-2015-12-550475. Epub 2016 Apr 5. Review.

21.

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.

Mielcarek M, Furlong T, O'Donnell PV, Storer BE, McCune JS, Storb R, Carpenter PA, Flowers ME, Appelbaum FR, Martin PJ.

Blood. 2016 Mar 17;127(11):1502-8. doi: 10.1182/blood-2015-10-672071. Epub 2016 Jan 13.

22.

Resilience, health, and quality of life among long-term survivors of hematopoietic cell transplantation.

Rosenberg AR, Syrjala KL, Martin PJ, Flowers ME, Carpenter PA, Salit RB, Baker KS, Lee SJ.

Cancer. 2015 Dec 1;121(23):4250-7. doi: 10.1002/cncr.29651. Epub 2015 Aug 19.

23.

Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.

Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Savani BN, Veys PA, Bredeson CN, Giralt SA, LeMaistre CF.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1863-1869. doi: 10.1016/j.bbmt.2015.07.032. Epub 2015 Aug 7.

24.

Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease.

Inamoto Y, Sun YC, Flowers ME, Carpenter PA, Martin PJ, Li P, Wang R, Chai X, Storer BE, Shen TT, Lee SJ.

Biol Blood Marrow Transplant. 2015 Nov;21(11):2002-7. doi: 10.1016/j.bbmt.2015.07.013. Epub 2015 Jul 17.

25.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report.

Martin PJ, Lee SJ, Przepiorka D, Horowitz MM, Koreth J, Vogelsang GB, Walker I, Carpenter PA, Griffith LM, Akpek G, Mohty M, Wolff D, Pavletic SZ, Cutler CS.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1343-59. doi: 10.1016/j.bbmt.2015.05.004. Epub 2015 May 15. Review.

26.

Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia.

Mehta PA, Zhang MJ, Eapen M, He W, Seber A, Gibson B, Camitta BM, Kitko CL, Dvorak CC, Nemecek ER, Frangoul HA, Abdel-Azim H, Kasow KA, Lehmann L, Gonzalez Vicent M, Diaz Pérez MA, Ayas M, Qayed M, Carpenter PA, Jodele S, Lund TC, Leung WH, Davies SM.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1273-7. doi: 10.1016/j.bbmt.2015.04.008. Epub 2015 Apr 10.

27.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.

Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, Hoodin F, Johnston L, Lawitschka A, McDonald GB, Opipari AW, Savani BN, Schultz KR, Smith SR, Syrjala KL, Treister N, Vogelsang GB, Williams KM, Pavletic SZ, Martin PJ, Lee SJ, Couriel DR.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1167-87. doi: 10.1016/j.bbmt.2015.03.024. Epub 2015 Mar 31.

28.

Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.

Perales MA, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, Evens AM, Laport GG, Moskowitz CH, Popat U, Reddy NM, Shea TC, Vose JM, Schriber J, Savani BN, Carpenter PA; American Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Jun;21(6):971-83. doi: 10.1016/j.bbmt.2015.02.022. Epub 2015 Mar 12.

29.

Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial.

Mielcarek M, Furlong T, Storer BE, Green ML, McDonald GB, Carpenter PA, Flowers ME, Storb R, Boeckh M, Martin PJ.

Haematologica. 2015 Jun;100(6):842-8. doi: 10.3324/haematol.2014.118471. Epub 2015 Feb 14.

30.

Failure-free survival after initial systemic treatment of chronic graft-versus-host disease.

Inamoto Y, Flowers ME, Sandmaier BM, Aki SZ, Carpenter PA, Lee SJ, Storer BE, Martin PJ.

Blood. 2014 Aug 21;124(8):1363-71. doi: 10.1182/blood-2014-03-563544. Epub 2014 May 29.

31.

Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.

Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, Shaughnessy P, Majhail N, Perales MA, Cutler CS, Bensinger W, Litzow MR, Mohty M, Champlin RE, Leather H, Giralt S, Carpenter PA.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1262-73. doi: 10.1016/j.bbmt.2014.05.003. Epub 2014 May 9.

32.

Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.

El-Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee SJ, Chen YB.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1341-8. doi: 10.1016/j.bbmt.2014.05.001. Epub 2014 May 9.

33.

Assessment of joint and fascia manifestations in chronic graft-versus-host disease.

Inamoto Y, Pidala J, Chai X, Kurland BF, Weisdorf D, Flowers ME, Palmer J, Arai S, Jacobsohn D, Cutler C, Jagasia M, Goldberg JD, Martin PJ, Pavletic SZ, Vogelsang GB, Lee SJ, Carpenter PA; Chronic GVHD Consortium.

Arthritis Rheumatol. 2014 Apr;66(4):1044-52. doi: 10.1002/art.38293.

34.

Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD.

Inamoto Y, Jagasia M, Wood WA, Pidala J, Palmer J, Khera N, Weisdorf D, Carpenter PA, Flowers ME, Jacobsohn D, Martin PJ, Lee SJ, Pavletic SZ; Chronic GVHD Consortium.

Bone Marrow Transplant. 2014 Apr;49(4):532-8. doi: 10.1038/bmt.2013.225. Epub 2014 Jan 27.

35.

Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.

Bubalo J, Carpenter PA, Majhail N, Perales MA, Marks DI, Shaughnessy P, Pidala J, Leather HL, Wingard J, Savani BN; American Society for Blood and Marrow Transplantation practice guideline committee.

Biol Blood Marrow Transplant. 2014 May;20(5):600-16. doi: 10.1016/j.bbmt.2014.01.019. Epub 2014 Jan 23. Review.

36.

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.

Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, Davies SM.

Blood. 2014 Mar 6;123(10):1615-20. doi: 10.1182/blood-2013-10-535716. Epub 2014 Jan 16.

37.

Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.

Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA; CIBMTR Pediatric Cancer Working Committee.

Pediatr Blood Cancer. 2014 Jun;61(6):1126-8. doi: 10.1002/pbc.24918. Epub 2014 Jan 4.

38.

Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

Palmer J, Williams K, Inamoto Y, Chai X, Martin PJ, Tomas LS, Cutler C, Weisdorf D, Kurland BF, Carpenter PA, Pidala J, Pavletic SZ, Wood W, Jacobsohn D, Arai S, Arora M, Jagasia M, Vogelsang GB, Lee SJ.

Biol Blood Marrow Transplant. 2014 Mar;20(3):337-44. doi: 10.1016/j.bbmt.2013.11.025. Epub 2013 Dec 4.

39.

Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease.

Inamoto Y, Martin PJ, Storer BE, Mielcarek M, Storb RF, Carpenter PA.

Haematologica. 2014 Feb;99(2):385-91. doi: 10.3324/haematol.2013.093062. Epub 2013 Sep 20.

40.

Relationship of body mass index and arm anthropometry to outcomes after pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies.

Hoffmeister PA, Storer BE, Macris PC, Carpenter PA, Baker KS.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1081-6. doi: 10.1016/j.bbmt.2013.04.017. Epub 2013 Apr 25.

41.

Characteristics of chronic GVHD after cord blood transplantation.

Newell LF, Flowers ME, Gooley TA, Milano F, Carpenter PA, Martin PJ, Delaney C.

Bone Marrow Transplant. 2013 Oct;48(10):1285-90. doi: 10.1038/bmt.2013.48. Epub 2013 Apr 15.

42.

Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.

Inamoto Y, Storer BE, Petersdorf EW, Nelson JL, Lee SJ, Carpenter PA, Sandmaier BM, Hansen JA, Martin PJ, Flowers ME.

Blood. 2013 Jun 20;121(25):5098-103. doi: 10.1182/blood-2012-10-464198. Epub 2013 Apr 1.

43.

Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome.

Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA; CIBMTR Pediatric Cancer Working Committee.

Biol Blood Marrow Transplant. 2013 Jun;19(6):893-7. doi: 10.1016/j.bbmt.2013.02.017. Epub 2013 Mar 1.

44.

Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.

Inamoto Y, Storer BE, Lee SJ, Carpenter PA, Sandmaier BM, Flowers ME, Martin PJ.

Blood. 2013 Mar 21;121(12):2340-6. doi: 10.1182/blood-2012-11-465583. Epub 2013 Jan 15.

45.

Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease.

Palmer JM, Lee SJ, Chai X, Storer BE, Flowers ME, Schultz KR, Inamoto Y, Cutler C, Pidala J, Arora M, Jacobsohn DA, Carpenter PA, Pavletic SZ, Martin PJ.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1649-55. doi: 10.1016/j.bbmt.2012.05.005. Epub 2012 Jun 9.

46.

Clinical benefit of response in chronic graft-versus-host disease.

Inamoto Y, Martin PJ, Chai X, Jagasia M, Palmer J, Pidala J, Cutler C, Pavletic SZ, Arora M, Jacobsohn D, Carpenter PA, Flowers ME, Khera N, Vogelsang GB, Weisdorf D, Storer BE, Lee SJ; Chronic GVHD Consortium.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1517-24. doi: 10.1016/j.bbmt.2012.05.016. Epub 2012 Jun 6.

47.

Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia.

Veys P, Wynn RF, Ahn KW, Samarasinghe S, He W, Bonney D, Craddock J, Cornish J, Davies SM, Dvorak CC, Duerst RE, Gross TG, Kapoor N, Kitko C, Krance RA, Leung W, Lewis VA, Steward C, Wagner JE, Carpenter PA, Eapen M.

Blood. 2012 Jun 21;119(25):6155-61. doi: 10.1182/blood-2012-01-405795. Epub 2012 May 9.

48.

Success of allogeneic marrow transplantation for children with severe aplastic anaemia.

Burroughs LM, Woolfrey AE, Storer BE, Deeg HJ, Flowers ME, Martin PJ, Carpenter PA, Doney K, Appelbaum FR, Sanders JE, Storb R.

Br J Haematol. 2012 Jul;158(1):120-8. doi: 10.1111/j.1365-2141.2012.09130.x. Epub 2012 Apr 26.

49.

First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63. doi: 10.1016/j.bbmt.2012.04.005. Epub 2012 Apr 14. Review.

50.

Secondary treatment of acute graft-versus-host disease: a critical review.

Martin PJ, Inamoto Y, Flowers ME, Carpenter PA.

Biol Blood Marrow Transplant. 2012 Jul;18(7):982-8. doi: 10.1016/j.bbmt.2012.04.006. Epub 2012 Apr 14. Review.

Supplemental Content

Loading ...
Support Center